Table 1 Clinical baseline data of patients in the discovery cohort
| Â | CAD-ONLY | CAD-T2DM | P value |
|---|---|---|---|
n = 685 | n = 254 | ||
Demographic data | |||
 Age (years) | 62.60 (56.00,70.20) | 64.40 (57.55,71.85) | 0.030 |
 Sex (male), % | 83.50 | 72.05 |  < 0.001 |
BMI (kg/m2) | 24.00 (22.00,26.00) | 24.50 (22.00,27.00) | 0.011 |
Comorbidities | |||
 Hypertension, % | 57.08 | 65.75 | 0.016 |
 Hyperlipidemia, % | 10.51 | 12.60 | 0.365 |
Biochemical measurements | |||
 ALT, U/L | 24.00 (18,34) | 24.00 (18,34) | 0.633 |
 AST, U/L | 24.00 (20,30) | 23.00 (19,30) | 0.065 |
 eGFR, ml/min/1.73 m2 | 88.81 (74.24,104.60) | 87.53 (69.28,103.51) | 0.475 |
 CK, U/L | 88.00 (64.00,129.00) | 85.00 (57.50,110.00) | 0.028 |
 CKMB, U/L | 6.25 (4.50,8.73) | 7.00 (5.00,9.20) | 0.038 |
 CREA, μmol/L | 83 (71,96) | 82 (69,97) | 0.611 |
 CHOL, mmol/L | 4.07 (3.49,4.85) | 4.18 (3.56,4.91) | 0.243 |
 LDLC, mmol/L | 2.44 (1.88,3.16) | 2.46 (1.91,3.03) | 0.777 |
 HDLC, mmol/L | 0.92 (0.79,1.10) | 0.955 (0.79,1.09) | 0.799 |
 APOA, g/L | 1.00 (0.86,1.17) | 1.01 (0.86,1.20) | 0.579 |
 TG, mmol/L | 1.30 (0.97,1.78) | 1.48 (1.11,2.11) |  < 0.001 |
 Lp(a), mg/L | 179.40 (86.74,428.64) | 178.09 (79.86,361.14) | 0.333 |
 proBNP, pg/mL | 197.10 (63.19,672.28) | 254.70 (85.75,878.00) | 0.082 |
 GLUC, mmol/L | 5.45 (4.90,6.22) | 7.90 (6.33,10.84) |  < 0.001 |
 HbA1c, % | 6.00 (5.70,6.30) | 7.40 (6.60,8.55) |  < 0.001 |